Lineage Cell Therapeutics (LCTX) closed at $0.99 on November 12, 2026, down 10.8% from the previous close, on volume of 1,277,936 shares (30-day average 1,341,160).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Diagonal Call Spread | 18-Dec-26 : 17-Jun-272 : 1 C | 380 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
Lineage Therapeutics Acquires NeuroAirmid, Expanding Cell Therapy Pipeline
TipRanks (Thu, 12-Nov 4:45 PM ET)
Lineage Cell Therapeutics GAAP EPS of -$0.03 in-line, revenue of $1.43M misses by $0.56M
Seeking Alpha News (Thu, 12-Nov 4:15 PM ET)
Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire (Thu, 12-Nov 4:05 PM ET)
Business Wire (Thu, 12-Nov 4:03 PM ET)
Here are the major earnings after the close Thursday
Seeking Alpha News (Thu, 12-Nov 10:00 AM ET)
Lineage Cell Therapeutics Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 5:35 PM ET)
Business Wire (Thu, 5-Nov 8:00 AM ET)
Lineage Provides Update on ReSonance Program for Hearing Loss
Business Wire (Thu, 29-Oct 8:00 AM ET)
Business Wire (Tue, 8-Sep 8:00 AM ET)
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Lineage Cell Therapeutics trades on the AMEX stock market under the symbol LCTX.
As of November 12, 2026, LCTX stock price declined to $0.99 with 1,277,936 million shares trading.
LCTX has a beta of 1.30, meaning it tends to be more sensitive to market movements. LCTX has a correlation of 0.11 to the broad based SPY ETF.
LCTX has a market cap of $250.45 million. This is considered a Small Cap stock.
Last quarter Lineage Cell Therapeutics reported $1 million in Revenue and -$.03 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.01.
In the last 3 years, LCTX traded as high as $2.09 and as low as $.37.
The top ETF exchange traded funds that LCTX belongs to (by Net Assets): VTI, IWM, VXF, IWO, IBB.
LCTX has underperformed the market in the last year with a price return of -45.6% while the SPY ETF gained +12.0%. LCTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.6% and -4.8%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
LCTX support price is $1.07 and resistance is $1.16 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LCTX shares will trade within this expected range on the day.
